Newsroom | 72952 results
Sorted by: Latest
-
Shape Memory Medical Secures $10 Million Financing Led by August Global Partners to Advance Aortic Clinical Programs
SAN JOSE, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., developer of proprietary shape memory polymer technology for endovascular embolization, today announced the closing of a $10 million convertible note financing led by new investor August Global Partners (AGP), joined by fellow new investor Taiwania Capital. The financing provides capital to support continued clinical development of the company’s aortic portfolio, including patient follow-up and data collection in the AAA-SHAPE Pivota...
-
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These...
-
Molina Healthcare of Michigan Donates $85,000 to Support Two Organizations Addressing Hunger and Housing in Bay and Saginaw Counties
BAY CITY, Mich.--(BUSINESS WIRE)--Molina Healthcare of Michigan donates $85,000 to support two organizations addressing hunger and housing in Bay and Saginaw counties....
-
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study
MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates...
-
AArete Recognized Among Forbes’ World’s Best Management Consulting Firms for Fifth Consecutive Year
CHICAGO--(BUSINESS WIRE)--AArete, a leading global management and technology consulting firm, was recently named among Forbes’ World’s Best Management Consulting Firms 2026....
-
Baron & Budd Announces Spring 2026 Mesothelioma Cancer Victims Memorial Scholarship Winners
DALLAS--(BUSINESS WIRE)--The nationally recognized law firm Baron & Budd selected Bailey Davis and Matthew Moran as the winners of the Mesothelioma Cancer Victims Memorial Scholarship. Each winner will receive a $2,500 scholarship paid directly to the financial aid accounts at their universities. Applicants were asked to submit a written or video essay about how cancer has impacted their lives. Bailey Davis was selected as the winner of the written essay contest after a competitive review b...
-
AmeriHealth Caritas Makes Strategic Investment in Deon Health
NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--AmeriHealth Caritas announced today a strategic investment in Deon Health, a Michigan-based specialty managed care organization built specifically to serve people with intellectual and developmental disabilities (I/DD). The investment will support Deon Health's work to advance specialized, coordinated care for people with I/DD through a purpose-built care model centered on individual needs, choices, and local communities, supported by specialized technology...
-
The More Life Company Corp. Announces New U.S. Trading Symbol
TORONTO--(BUSINESS WIRE)--The More Life Company Corp. (the “Company”) (CSE: MLCO) formerly Mountain Valley MD Holdings Inc., further to its press release dated August 18, 2026 announcing the completion of its corporate name change, is pleased to announce that its common shares will continue to be quoted on the OTCID under the new trading symbol “TMLCF”, effective at the opening of trading on August 21, 2026. The Company commenced trading on the Canadian Securities Exchange under its new name an...
-
HCA Healthcare, Inc. to Present at September Conferences
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences: September 9, 2026, at 10:15am ET at the Wells Fargo Healthcare Conference September 15, 2026, at 1:50pm CT at the Jefferies Healthcare Conference A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com. Dates and tim...
-
Fortive Increases Regular Quarterly Dividend
EVERETT, Wash.--(BUSINESS WIRE)--Fortive Corporation (“Fortive”) (NYSE: FTV) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.07 per share of its common stock, par value $0.01 per share, payable on September 25, 2026 to common stockholders of record on September 4, 2026. This declared dividend represents an increase of 16.7% over the prior quarterly dividend. Although Fortive expects to pay dividends on a quarterly basis, any subsequent declaration of...